Genvec (Genvec) Days Payable : 0.00 (As of Mar. 2017)

View and export this data going back to 2000. Start your Free Trial

What is Genvec Days Payable?

Genvec's average Accounts Payable for the three months ended in Mar. 2017 was $1.30 Mil. Genvec's Cost of Goods Sold for the three months ended in Mar. 2017 was $0.00 Mil.

The historical rank and industry rank for Genvec's Days Payable or its related term are showing as below:

GNVC's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 152.29
* Ranked among companies with meaningful Days Payable only.

Genvec's Days Payable stayed the same from Mar. 2016 (0.00) to Mar. 2017 (0.00). stayed the same

Genvec Days Payable Historical Data

The historical data trend for Genvec's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genvec Days Payable Chart

Genvec Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Days Payable

Get a 7-Day Free Trial

Genvec Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Genvec's Days Payable

For the Biotechnology subindustry, Genvec's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genvec's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genvec's Days Payable distribution charts can be found below:

* The bar in red indicates where Genvec's Days Payable falls into.

Genvec Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Genvec's Days Payable for the fiscal year that ended in Dec. 2016 is calculated as

	Days Payable (A: Dec. 2016 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2015 )	+	Accounts Payable (A: Dec. 2016 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2016 )	*	Days in Period
=	( (1.096	+	0.957)	/	2 )	/	0	*	365
=	1.0265					/	0	*	365
=	N/A

Genvec's Days Payable for the quarter that ended in Mar. 2017 is calculated as:

	Days Payable (Q: Mar. 2017 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2016 )	+	Accounts Payable (Q: Mar. 2017 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2017 )	*	Days in Period
=	( (0.957	+	1.635)	/	2 )	/	0	*	365 / 4
=	1.296					/	0	*	365 / 4
=	N/A

Genvec Days Payable Related Terms

Thank you for viewing the detailed overview of Genvec's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Genvec (Genvec) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genvec Inc (NAS:GNVC) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.genvec.com

Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV.

Executives

Wayne T Hockmeyer	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Michael Richman	director	2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
Marc R Schneebaum	director	GENVEC, INC., 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Stefan Loren	director	3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Douglas J Swirsky	director, officer: President and CEO	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Willam N Kelley	director	MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Mmcap International Inc. Spc	10 percent owner	C/O MOURANT GOVERNANCE SVCS (CAYMAN) LTD, 94 SOLARIS AVE., CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Ecor1 Capital Fund Qualified, L.p.	other: See Explanation of Responses	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p.	other: See Explanation of Responses	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Zola P Horovitz	director	C/O GENAERA CORP, 5110 CAMPUS DDRIVE, PLYMOUTH MEETING PA 19462
Cynthia Collins	director, officer: President & CEO	65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Adel Mahmoud	director
Joshua Ruch	director	4 DUNE ROAD, EAST QUOGUE NY 11942

Genvec (Genvec) Headlines

From GuruFocus

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-07-2010

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-06-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus • 08-07-2009

GenVec Inc. Reports Operating Results (10-K)

By gurufocus 10qk • 03-11-2011

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus • 05-08-2009